Drugs / Carelizumab
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04110093 | Mar 2019 → Aug 2021 | colorectal cancer | Shanghai Changzheng Hospital | Unknown | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06611826 | Sep 2024 → Sep 2028 expected | nasopharyngeal carcinoma | Zhejiang Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT04934618 | May 2020 → May 2023 | gastric cancer | Nanfang Hospital, Southern Medical University | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04335006 | Jul 2020 → Apr 2023 | triple-negative breast carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Carelizumab | “The R-GEP regimen is as follows: Gemcitabine (G; 1.0 g/m2, d1, d8) in combination with recombinant human vascular endothelial growth factor (E; 150 mg, continuous intravenous...” NCT06611826 ↗3“including nivolumab (3mg/kg, ivgtt, q2w), Carelizumab (200mg, ivgtt, q3w), Sintilimab (200mg, ivgtt, q3w), Toripalimab(240mg ivgtt, q3w).” NCT04110093 ↗ |
| Route | Intravenous | “Carelizumab (200mg, ivgtt, q3w)” NCT04110093 ↗ |